StockGuide AI
Track Stocks
EN RU ES
Eli Lilly

Eli Lilly

Price: 1136.37

Company and Business Model

Eli Lilly is a global healthcare company that focuses on the discovery, development, and commercialization of pharmaceuticals. Its core products include treatments for diabetes, oncology, immunology, and neurodegenerative diseases. Major business segments consist of diabetes care, oncology, and neuroscience, with significant revenue generated from insulin products and cancer therapies. The company is recognized for its innovative drug pipeline and strong market presence in the healthcare sector.

Investment Profile

Eli Lilly's stock is positioned as a balanced investment, appealing to investors seeking moderate growth and some income through dividends. The company demonstrates stable revenue growth and a consistent dividend yield, making it suitable for those looking for a mix of capital appreciation and income. Its established market presence and ongoing product development contribute to a favorable risk-return profile.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
28.20 OK
Revenue QoQ — quarter-over-quarter revenue growth
2.6% ↑
EPS surprise
22.7% better than expected
20d volatility
1.9% stable
Dividend yield
0.6% low last ex-date: 2026-05-15
FMP / FinFeed data updated: 2026-06-09

Forecast impact

positive
Target Raised · Jefferies · valid until 2026-07-09 · updated 2026-06-11
Target +18.8% target fill 84.2%
Reaction D5 pending · D10 pending fresh confirmed · market trust
Impact Potential +6 · Risk -3 up to 30 days or until target is reached
Reco: Buy Potential: 84 Risk: 26 Updated: 2026-06-11 05:32
How recommendation works
Why AI thinks so:
Strong fundamentals and positive momentum support growth outlook.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-05-18 04:09 Hold Buy Strong fundamentals and positive short-term momentum.
2026-05-10 02:33 Buy Hold Weak momentum and high risk; mixed analyst signals.
2026-05-08 14:57 — Buy Solid fundamentals but mixed momentum signals.
Analyst forecasts
Date Analyst Action Target Price Then
2026-06-09 15:51 Jefferies Target Raised 1330 → 1350 1143.35
2026-05-26 09:26 HSBC Target Raised — → 1251 1065
2026-05-26 07:05 Leerink Partners Update — → 1119 1065
Merck Redwire Eli Lilly

The Pharmaceutical Industry Embraces Space: Drug Development in Low Earth Orbit Gains Momentum

06/09/2026, 07:32 AM growth pharma space Merck Redwire Eli Lilly
The shift of pharmaceutical development to lower Earth orbit represents a significant evolution in the space economy, with the potential to enhance drug formulation and delivery methods. This trend could disrupt traditional pharmaceutical practices and create new investment opportunities as the space economy is projected to exceed $1 trillion by 2040.
Novo Nordisk Eli Lilly

Novo Nordisk and Eli Lilly Compete for Dominance in the GLP-1 Pill Market Ahead of Medicare Coverage

06/08/2026, 05:48 PM business review healthcare Novo Nordisk Eli Lilly
Novo Nordisk and Eli Lilly are intensifying their competition in the GLP-1 pill market as they prepare for Medicare coverage, which could significantly increase access to their obesity treatments. Both companies are focusing on marketing strategies to appeal to seniors, who will soon be able to access these medications at a reduced cost.
Wells Fargo Intel Broadcom Eli Lilly

Stock Market Experiences Significant Decline Following Strong Jobs Report and Disappointing Earnings from Tech Companies

06/06/2026, 05:32 PM economy review tech semiconductors Wells Fargo Intel Broadcom Eli Lilly
Last week's stock market experienced a significant downturn, primarily driven by disappointing earnings from major tech companies and a strong jobs report that diminished expectations for a Federal Reserve interest rate cut. This shift has raised concerns about the sustainability of recent market highs and the potential impact of increased stock supply from upcoming IPOs.
Eli Lilly

Eli Lilly’s Business Development Head Jacob Van Naarden Signals Increased M&A Activity as Company Pursues New Opportunities

06/03/2026, 11:33 AM business announcement healthcare Eli Lilly
Eli Lilly is leveraging its significant financial strength, driven by its successful weight loss drugs, to pursue an aggressive acquisition strategy aimed at diversifying its drug pipeline and expanding into new therapeutic areas. This shift marks a notable change in Lilly's approach to dealmaking as it seeks to capitalize on its recent growth.